Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis Who Had Inadequate Responses to Apremilast at Week 24 in the Phase 3 POETYK PSO-1 and PSO-2 Trials
Authors: April W Armstrong, Richard B Warren, Howard Sofen, Lynda Spelman, Craig Leonardi, Subhashis Banerjee, Tao Wang, John Throup, Elizabeth Colston, Andrew Napoli, Alexa B Kimball